Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is any type of epithelial lung cancer other than small cell lung cancer (SCLC). There are several types of NSCLCs but the most common are squamous cell carcinoma, large cell carcinoma and adenocarcinoma. Although NSCLCs are associating with cigarette smoking, adenocarcinomas may be found in patients who never smoked.
It is estimated that there will be approximately 240,000 new cases of lung cancer this year and at least 127,000 deaths. It is the leading cause of cancer-related mortality in the United States.
Assistance Information
Dollar cap is shared across assistance types.
Other Insurance — Up to 500% FPL
| Assistance Type | Status | Max Amount |
|---|---|---|
| Copay | Open | $4,000 |
| Medical Expenses | Open | $4,000 |
| Travel Expense | Open | $500 |
Private Insurance — Up to 500% FPL
| Assistance Type | Status | Max Amount |
|---|---|---|
| Copay | Open | $4,000 |
| Medical Expenses | Open | $4,000 |
| Premium | Open | $4,000 |
| Travel Expense | Open | $500 |
Diagnosis Codes
- C34 Malignant neoplasm of bronchus and lung
- C34.0 Malignant neoplasm of main bronchus
- C34.00 Malignant neoplasm of unspecified main bronchus
- C34.01 Malignant neoplasm of right main bronchus
- C34.02 Malignant neoplasm of left main bronchus
- C34.1 Malignant neoplasm of upper lobe, bronchus or lung
- C34.10 Malignant neoplasm of upper lobe, unspecified bronchus or lung
- C34.11 Malignant neoplasm of upper lobe, right bronchus or lung
- C34.12 Malignant neoplasm of upper lobe, left bronchus or lung
- C34.2 Malignant neoplasm of middle lobe, bronchus or lung
- C34.3 Malignant neoplasm of lower lobe, bronchus or lung
- C34.30 Malignant neoplasm of lower lobe, unspecified bronchus or lung
- C34.31 Malignant neoplasm of lower lobe, right bronchus or lung
- C34.32 Malignant neoplasm of lower lobe, left bronchus or lung
- C34.8 Malignant neoplasm of overlapping sites of bronchus and lung
- C34.80 Malignant neoplasm of overlapping sites of unspecified bronchus and lung
- C34.81 Malignant neoplasm of overlapping sites of right bronchus and lung
- C34.82 Malignant neoplasm of overlapping sites of left bronchus and lung
- C34.9 Malignant neoplasm of unspecified part of bronchus or lung
- C34.90 Malignant neoplasm of unspecified part of unspecified bronchus or lung
- C34.91 Malignant neoplasm of unspecified part of right bronchus or lung
- C34.92 Malignant neoplasm of unspecified part of left bronchus or lung
Covered Medications
- Lurbinectedin
- Zepzelca
- Avopef
- Etoposide
- Toposar
- Etopophos
- Etoposide Phosphate
- Hycamtin
- Topotecan HCl
- Imdelltra
- Tarlatamab-dlle
- Cytalux
- Pafolacianine Sodium
- Adriamycin
- DOXOrubicin HCl
- Avgemsi
- Gemcitabine HCl
- Inlexzo
- Gemcitabine HCl-NaCl
- Infugem
- Cyramza
- Ramucirumab
- Ipilimumab
- Yervoy
- Cemiplimab-rwlc
- Libtayo
- Nivolumab
- Opdivo
- Durvalumab
- Imfinzi
- Amivantamab-vmjw
- Rybrevant
- Dacomitinib
- Vizimpro
- Erlotinib HCl
- Tarceva
- Exkivity
- Mobocertinib Succinate
- Necitumumab
- Portrazza
- Osimertinib Mesylate
- Tagrisso
- Beizray
- DOCEtaxel
- Docivyx
- Abraxane
- PACLitaxel Protein-Bound Part
- Vinorelbine Tartrate
- Alecensa
- Alectinib HCl
- Alunbrig
- Brigatinib
- Ceritinib
- Zykadia
- Crizotinib
- Xalkori
- Lorbrena
- Lorlatinib
- Dabrafenib Mesylate
- Tafinlar
- Lumakras
- Sotorasib
- Mekinist
- Trametinib Dimethyl Sulfoxide
- Capmatinib HCl
- Tabrecta
- Tepmetko
- Tepotinib HCl
- Entrectinib
- Rozlytrek
- Gavreto
- Pralsetinib
- Retevmo
- Selpercatinib
- Enhertu
- Fam-Trastuzumab Deruxtec-nxki
- Imjudo
- Tremelimumab-actl
- Adagrasib
- Krazati
- Braftovi
- Encorafenib
- Binimetinib
- Mektovi
- Augtyro
- Repotrectinib
- PACLitaxel
- Lazcluze
- Lazertinib Mesylate
- Bizengri (750 MG Dose)
- Zenocutuzumab-zbco(750MG Dose)
- Nivolumab-Hyaluronidase-nvhy
- Opdivo Qvantig
- Afatinib Dimaleate
- Gilotrif
- Gefitinib
- Iressa
- Ensacove
- Ensartinib HCl
- Ibtrozi
- Taletrectinib Adipate
- Datopotamab Deruxtecan-dlnk
- Datroway
- Photofrin
- Porfimer Sodium
- Beizray
- DOCEtaxel & Albumin
- Amivantamab-Hyaluronidase-lpuj
- Rybrevant Faspro
- Alimta
- PEMEtrexed Disodium
- Pemrydi RTU
- Avastin
- Bevacizumab
- Bevacizumab-adcd
- Vegzelma
- Bevacizumab-awwb
- Mvasi
- Bevacizumab-bvzr
- Zirabev
- Alymsys
- Bevacizumab-maly
- Emrelis
- Telisotuzumab Vedotin-tllv
- PEMEtrexed
- Pemfexy
- Axtle
- PEMEtrexed Dipotassium
- PEMEtrexed Ditromethamine
- Keytruda
- Pembrolizumab
- Atezolizumab
- Tecentriq
- Atezolizumab-Hyaluronidas-tqjs
- Tecentriq Hybreza
- Hernexeos
- Zongertinib
- Bevacizumab-nwgd
- Jobevne
- Keytruda Qlex
- Pembrolizumab-Berahyalur-pmph
- Hyrnuo
- Sevabertinib
Resources
CancerCare
Caregiver Resources
ARCH National Respite Network and Resource Center
National Alliance for Caregiving
Other Patient Assistance Organizations
Non-small cell lung cancer (NSCLC) is any type of epithelial lung cancer other than small cell lung cancer (SCLC). There are several types of NSCLCs but the most common are squamous cell carcinoma, large cell carcinoma and adenocarcinoma. Although NSCLCs are associating with cigarette smoking, adenocarcinomas may be found in patients who never smoked.
It is estimated that there will be approximately 240,000 new cases of lung cancer this year and at least 127,000 deaths. It is the leading cause of cancer-related mortality in the United States.
Assistance Information
Dollar cap is shared across assistance types.
Public Insurance — Up to 500% FPL
| Assistance Type | Status | Max Amount |
|---|---|---|
| Copay | At Capacity | $4,000 |
| Medical Expenses | At Capacity | $4,000 |
| Premium | At Capacity | $4,000 |
| Travel Expense | At Capacity | $500 |
Diagnosis Codes
- C34 Malignant neoplasm of bronchus and lung
- C34.0 Malignant neoplasm of main bronchus
- C34.00 Malignant neoplasm of unspecified main bronchus
- C34.01 Malignant neoplasm of right main bronchus
- C34.02 Malignant neoplasm of left main bronchus
- C34.1 Malignant neoplasm of upper lobe, bronchus or lung
- C34.10 Malignant neoplasm of upper lobe, unspecified bronchus or lung
- C34.11 Malignant neoplasm of upper lobe, right bronchus or lung
- C34.12 Malignant neoplasm of upper lobe, left bronchus or lung
- C34.2 Malignant neoplasm of middle lobe, bronchus or lung
- C34.3 Malignant neoplasm of lower lobe, bronchus or lung
- C34.30 Malignant neoplasm of lower lobe, unspecified bronchus or lung
- C34.31 Malignant neoplasm of lower lobe, right bronchus or lung
- C34.32 Malignant neoplasm of lower lobe, left bronchus or lung
- C34.8 Malignant neoplasm of overlapping sites of bronchus and lung
- C34.80 Malignant neoplasm of overlapping sites of unspecified bronchus and lung
- C34.81 Malignant neoplasm of overlapping sites of right bronchus and lung
- C34.82 Malignant neoplasm of overlapping sites of left bronchus and lung
- C34.9 Malignant neoplasm of unspecified part of bronchus or lung
- C34.90 Malignant neoplasm of unspecified part of unspecified bronchus or lung
- C34.91 Malignant neoplasm of unspecified part of right bronchus or lung
- C34.92 Malignant neoplasm of unspecified part of left bronchus or lung
Covered Medications
- Lurbinectedin
- Zepzelca
- Avopef
- Etoposide
- Toposar
- Etopophos
- Etoposide Phosphate
- Hycamtin
- Topotecan HCl
- Imdelltra
- Tarlatamab-dlle
- Cytalux
- Pafolacianine Sodium
- Adriamycin
- DOXOrubicin HCl
- Avgemsi
- Gemcitabine HCl
- Inlexzo
- Gemcitabine HCl-NaCl
- Infugem
- Cyramza
- Ramucirumab
- Ipilimumab
- Yervoy
- Cemiplimab-rwlc
- Libtayo
- Nivolumab
- Opdivo
- Durvalumab
- Imfinzi
- Amivantamab-vmjw
- Rybrevant
- Dacomitinib
- Vizimpro
- Erlotinib HCl
- Tarceva
- Exkivity
- Mobocertinib Succinate
- Necitumumab
- Portrazza
- Osimertinib Mesylate
- Tagrisso
- Beizray
- DOCEtaxel
- Docivyx
- Abraxane
- PACLitaxel Protein-Bound Part
- Vinorelbine Tartrate
- Alecensa
- Alectinib HCl
- Alunbrig
- Brigatinib
- Ceritinib
- Zykadia
- Crizotinib
- Xalkori
- Lorbrena
- Lorlatinib
- Dabrafenib Mesylate
- Tafinlar
- Lumakras
- Sotorasib
- Mekinist
- Trametinib Dimethyl Sulfoxide
- Capmatinib HCl
- Tabrecta
- Tepmetko
- Tepotinib HCl
- Entrectinib
- Rozlytrek
- Gavreto
- Pralsetinib
- Retevmo
- Selpercatinib
- Enhertu
- Fam-Trastuzumab Deruxtec-nxki
- Imjudo
- Tremelimumab-actl
- Adagrasib
- Krazati
- Braftovi
- Encorafenib
- Binimetinib
- Mektovi
- Augtyro
- Repotrectinib
- PACLitaxel
- Lazcluze
- Lazertinib Mesylate
- Bizengri (750 MG Dose)
- Zenocutuzumab-zbco(750MG Dose)
- Nivolumab-Hyaluronidase-nvhy
- Opdivo Qvantig
- Afatinib Dimaleate
- Gilotrif
- Gefitinib
- Iressa
- Ensacove
- Ensartinib HCl
- Ibtrozi
- Taletrectinib Adipate
- Datopotamab Deruxtecan-dlnk
- Datroway
- Photofrin
- Porfimer Sodium
- Beizray
- DOCEtaxel & Albumin
- Amivantamab-Hyaluronidase-lpuj
- Rybrevant Faspro
- Alimta
- PEMEtrexed Disodium
- Pemrydi RTU
- Avastin
- Bevacizumab
- Bevacizumab-adcd
- Vegzelma
- Bevacizumab-awwb
- Mvasi
- Bevacizumab-bvzr
- Zirabev
- Alymsys
- Bevacizumab-maly
- Emrelis
- Telisotuzumab Vedotin-tllv
- PEMEtrexed
- Pemfexy
- Axtle
- PEMEtrexed Dipotassium
- PEMEtrexed Ditromethamine
- Keytruda
- Pembrolizumab
- Atezolizumab
- Tecentriq
- Atezolizumab-Hyaluronidas-tqjs
- Tecentriq Hybreza
- Hernexeos
- Zongertinib
- Bevacizumab-nwgd
- Jobevne
- Keytruda Qlex
- Pembrolizumab-Berahyalur-pmph
- Hyrnuo
- Sevabertinib
Resources
CancerCare
Caregiver Resources
ARCH National Respite Network and Resource Center
National Alliance for Caregiving
Other Patient Assistance Organizations
